Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320310 | 0.87 | LATS1 (0.37) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2319171 | 0.87 | ESRRG (0.41) | ALDH1A1TSHRHTT | |
| SCHEMBL2320144 | 0.86 | PTGS2 (0.33) | ALDH1A1MEN1KMT2APTGS2PTGS1 | |
| SCHEMBL2317775 | 0.85 | HTR6 (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2319582 | 0.85 | EED (0.39) | KDM4EKMT2AFLT3 | |
| SCHEMBL2319888 | 0.84 | PTPN11 (0.34) | ALDH1A1KDM4EMEN1KMT2APTGS2 | |
| SCHEMBL12444978 | 0.83 | EED (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1933995 | 0.83 | MAPT (0.44) | MAPTKDM4ELMNAHTTGAA | |
| SCHEMBL2317034 | 0.83 | ACHE (0.46) | FLT3PTGS2 | |
| SCHEMBL2319238 | 0.83 | CYP11B1 (0.39) | PTGS2PTGS1PTGDR2GBA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | MAPT 3798/4885ALDH1A1 305/4885KDM4E 3487/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | MAPT 3798/4885ALDH1A1 305/4885KDM4E 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.